The GAMetocyticidal activity of sulphadoxine-pyremthamine plus artesunate followed by a single dose of PrimaQuine
- Conditions
- ncomplicated febrile malariaInfections and InfestationsMalaria
- Registration Number
- ISRCTN61534963
- Lead Sponsor
- The Netherlands Foundation for the Advancement of Tropical Research (NWO-WOTRO) (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
1. Age more than three years
2. Residents of research area (5 km around the clinic)
3. Willingness to come for complete scheduled follow-up
4. Uncomplicated malaria with Plasmodium falciparum mono-infection
5. Parasitaemia of 500,000 to 900,000 parasites/ul
6. Temperature more than 37.5 and less than 39.5°C, or history of fever in the previous 24 hours
7. No history of adverse reactions to SP or PQ treatment
8. Understanding of the procedures of the study by parent or guardian and willing to participate by signing informed consent forms
1. General signs of severe malaria or haemoglobin count less than 8 g/dl
2. Presence of disease other than malaria causing febrile conditions
3. Unwilling to participate and sign informed consent forms
4. Eligibility for (or participation in) other malaria projects in the Korogwe area, notably the Intermittent Preventive Treatment of malaria in infants (IPTi) study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The following are assesed on days one, two, three, seven, 14, 28 and 42 after treatment:<br>1. Resolution of clinical symptoms <br>2. Haematological recovery<br>3. Presense of malaria parasites by microscopy and molecular technicques<br>4. Presence of sexual stage parasites by microscopy and molecular technicques
- Secondary Outcome Measures
Name Time Method 1. Haematological recovery in G6PD deficient and non deficient individuals<br>2. Selection of drug-resistant parasite strains after treatment